Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 16/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | TACR2 | P21452 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13619226 | 0.92 | TACR3 (0.53) | TACR3SLC2A1TACR2ADORA2AADORA1 | |
| SCHEMBL4356702 | 0.88 | TACR3 (0.56) | TACR3SLC2A1TACR2ADORA2AADORA1 | |
| SCHEMBL4358876 | 0.86 | TACR3 (0.47) | TACR3SLC2A1TACR2ADORA2AADORA1 | |
| SCHEMBL13619223 | 0.86 | TACR3 (0.54) | TACR3SLC2A1TACR2ADORA2AADORA1 | |
| SCHEMBL4355252 | 0.80 | TACR3 (0.53) | TACR3SLC2A1TACR2ADORA2AADORA1 | |
| SCHEMBL4357027 | 0.77 | TACR3 (0.46) | TACR3SLC2A1TACR2ADORA2AADORA1 | |
| SCHEMBL4355463 | 0.76 | TACR3 (0.48) | TACR3SLC2A1TACR2ADORA2AADORA1 | |
| SCHEMBL4361680 | 0.76 | TACR3 (0.45) | TACR3SLC2A1TACR2ADORA2AADORA1 | |
| SCHEMBL4363718 | 0.75 | TACR3 (0.43) | TACR3SLC2A1TACR2ADORA2AADORA1 | |
| SCHEMBL3244597 | 0.75 | CTSS (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| WO-2006067430-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | PNMT, SLC18A2, COMT | TACR3 2005/4885SLC2A1 1844/4885TACR2 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.